Comparable stake leader
Dan Yrigoyen
SEC ownership of Arch Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001537561.
Disclosed value leader
—
Comparable rows
0/7
Latest evidence
31 Aug 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Dan Yrigoyen
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
31 Aug 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001537561
- Issuer location
- Framingham, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Arch Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Dan Yrigoyen
Disclosed value leader
—
Comparable rows
0/7
Latest evidence
31 Aug 2023
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
7 rows are not safely comparable across share classes.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 7 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Dan Yrigoyen's linked filing trail.
Detailed SEC evidence table Showing 1-7 of 7 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Dan Yrigoyen |
3/4/5
VICE PRESIDENT, SALES
|
—
class O/S missing
|
—
500,000 shares
|
— | 10 Nov 2022 |
| Guy L. Fish |
3/4/5
Director
|
—
class O/S missing
|
—
250,000 shares
|
— | 10 Nov 2022 |
| James R. Sulat |
3/4/5
Director
|
—
class O/S missing
|
—
250,000 shares
|
— | 27 Sep 2021 |
| Punit Dhillon |
3/4/5
Director
|
—
class O/S missing
|
—
250,000 shares
|
— | 10 Nov 2022 |
| Laurence Hicks |
3/4/5
Director
|
—
mixed-class rows
|
—
30,876 shares
mixed-class rows
|
— | 31 Aug 2023 |
| Michael S. Abrams |
3/4/5
CHIEF FINANCIAL OFFICER
|
—
mixed-class rows
|
—
30,876 shares
mixed-class rows
|
— | 31 Aug 2023 |
| Terrence W. Norchi |
3/4/5
PRESIDENT AND CHIEF EXECUTIVE, Director
|
—
mixed-class rows
|
—
20,586 shares
mixed-class rows
|
— | 31 Aug 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 13 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-7 of 7 reporting-owner rows connected to Arch Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
7
Largest Forms 3/4/5 holder
James R. Sulat
Net 12M change
$0
Latest report
31 Aug 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| James R. Sulat | Director | Mixed | 27 Sep 2021 | |||
| Terrence W. Norchi | PRESIDENT AND CHIEF EXECUTIVE, Director | Mixed | 31 Aug 2023 | |||
| Dan Yrigoyen | Vice President, Sales | Mixed | 10 Nov 2022 | |||
| Laurence Hicks | Director | Mixed | 31 Aug 2023 | |||
| Guy L. Fish | Director | Mixed | 10 Nov 2022 | |||
| Punit Dhillon | Director | Mixed | 10 Nov 2022 | |||
| Michael S. Abrams | Chief Financial Officer | Mixed | 31 Aug 2023 |
Recent insider transactions for Arch Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.